Drug intelligence / Profile preview

AmnioBlast

Development stage
Preclinical
Administration
Intraarticular, Intramuscular, Soft Tissue Injection
01

Overview

**AmnioBlast** is a human amniotic membrane-based biologic product formulated as a micronized or injectable suspension derived from processed amniotic tissue, primarily used as a regenerative allograft for orthopedic and wound healing applications. It leverages the natural properties of amniotic membrane, including anti-inflammatory cytokines (e.g., IL-10, IL-1RA), growth factors (e.g., bFGF, EGF, PDGF, TGF-β), hyaluronic acid, and protease inhibitors (e.g., TIMPs), to promote tissue repair, reduce inflammation, inhibit fibrosis, and support epithelialization and cartilage regeneration. Developed for conditions like osteoarthritis, tendonitis, plantar fasciitis, and chronic wounds, it is injected intra-articularly or into soft tissues to stimulate endogenous healing without immunosuppression, though its use remains investigational for most indications per medical policies.[1][2][3]

Brand names
AmnioBlast
02

Targets

EGFR (Epidermal growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)IL-1R (Interleukin-1 receptor type 1 (IL-1R1))IL10RA (Interleukin-10 Receptor)MMP12 (Macrophage Metalloelastase)PDGFRA (Platelet-derived growth factor receptor alpha)FGF2IL1RN (Interleukin-1 receptor antagonist)IL10 (Interleukin-10)PDGF (Platelet-derived Growth Factor family)

Beyond the preview

Go deeper on AmnioBlast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AmnioBlast.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call